{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:37:24Z","timestamp":1782855444325,"version":"3.54.5"},"reference-count":33,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"ISS Amgen","award":["NHMRC 1108886"],"award-info":[{"award-number":["NHMRC 1108886"]}]},{"name":"ISS Amgen","award":["MRFF 1137462."],"award-info":[{"award-number":["MRFF 1137462."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Bisphosphonates have been reported to be cardioprotective in some, but not all, studies. It is unknown whether denosumab (Dmab) use protects against cardiovascular events (CVEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether oral bisphosphonate (oBP) or Dmab use is associated with CVEs in persons with incident fracture.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants with an incident minimal trauma fracture from the Sax Institute\u2019s 45 and Up Study, a population-based cohort from NSW, Australia, were followed between 2005\/2009 and 2017. Questionnaire data were linked to hospital admissions (Admitted Patients Data Collection [APDC]) by the Centre for Health Record Linkage). Medicare Benefit Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) data sets were provided by Services Australia. Data was stored in a secure computing environment (Secure Unified Research Environment). Fractures, CVEs, and comorbidities were identified from the APDC and oBP and Dmab medication from the PBS. oBP and Dmab users were matched to never users (NoRx) by propensity scores. The main outcome measures were association between oBP and Dmab with CVE (acute myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemic attack) and were determined using a stratified Cox's proportional hazards model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 880 pairs of oBP and NoRx (616 women) and 770 pairs of Dmab and NoRx (615 women) followed for \u223c4.3 years. CVE risk was similar for oBP and NoRx Hazard Ratios (HR) women, 0.88 [95% CI 0.65-1.18]; men, 1.07 [95% CI 0.72-1.57]). Similar findings were obtained for Dmab (Hazard Ratios (HR) women, 1.08 [95% CI 0.78-1.50]; men, 1.55 [95% CI 0.96-2.48]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>oBP and Dmab use was not associated with CVEs.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac669","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T09:30:02Z","timestamp":1669023002000},"page":"e110-e119","source":"Crossref","is-referenced-by-count":3,"title":["Antiresorptive Medication Use Is not Associated With Acute Cardiovascular Risk: An Observational Study"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9682-2313","authenticated-orcid":false,"given":"Dana","family":"Bliuc","sequence":"first","affiliation":[{"name":"Skeletal diseases Program, Garvan Institute of Medical Research , Sydney, NSW 2010 , Australia"},{"name":"School of Population Health, Faculty of Medicine and Health , UNSW Sydney, NSW 2052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6454-124X","authenticated-orcid":false,"given":"Thach","family":"Tran","sequence":"additional","affiliation":[{"name":"Skeletal diseases Program, Garvan Institute of Medical Research , Sydney, NSW 2010 , Australia"},{"name":"School of Clinical Medicine, Faculty of Medicine and Health , UNSW Sydney, NSW 2052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Skeletal diseases Program, Garvan Institute of Medical Research , Sydney, NSW 2010 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-2936","authenticated-orcid":false,"given":"Dunia","family":"Alarkawi","sequence":"additional","affiliation":[{"name":"Skeletal diseases Program, Garvan Institute of Medical Research , Sydney, NSW 2010 , Australia"},{"name":"School of Clinical Medicine, Faculty of Medicine and Health , UNSW Sydney, NSW 2052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0012-9627","authenticated-orcid":false,"given":"Dima A","family":"Alajlouni","sequence":"additional","affiliation":[{"name":"Skeletal diseases Program, Garvan Institute of Medical Research , Sydney, NSW 2010 , Australia"},{"name":"School of Clinical Medicine, Faculty of Medicine and Health , UNSW Sydney, NSW 2052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Blyth","sequence":"additional","affiliation":[{"name":"Concord Clinical School, University of Sydney , Sydney, NSW 2006 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"March","sequence":"additional","affiliation":[{"name":"Institute of Bone and Joint Research, University of Sydney , Sydney, NSW 2006 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-1944","authenticated-orcid":false,"given":"Robert D","family":"Blank","sequence":"additional","affiliation":[{"name":"Skeletal diseases Program, Garvan Institute of Medical Research , Sydney, NSW 2010 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5278-4527","authenticated-orcid":false,"given":"Jacqueline R","family":"Center","sequence":"additional","affiliation":[{"name":"Skeletal diseases Program, Garvan Institute of Medical Research , Sydney, NSW 2010 , Australia"},{"name":"School of Clinical Medicine, Faculty of Medicine and Health , UNSW Sydney, NSW 2052 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"18","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"25","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00198-018-4806-0","article-title":"Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study","volume":"30","author":"Bliuc","year":"2019","journal-title":"Osteoporos Int"},{"issue":"3","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"e180826","DOI":"10.1001\/jamanetworkopen.2018.0826","article-title":"Association of osteoporosis medication use after hip fracture with prevention of subsequent nonvertebral fractures: an instrumental variable analysis","volume":"1","author":"Desai","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00198-015-3415-4","article-title":"Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study","volume":"27","author":"Brozek","year":"2016","journal-title":"Osteoporosis Int"},{"issue":"6","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00223-019-00611-3","article-title":"Treatment effects of bisphosphonates and denosumab on survival and refracture from real-world data of hip-fractured patients","volume":"105","author":"Behanova","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00198-010-1411-2","article-title":"Oral bisphosphonates are associated with reduced mortality after hip fracture","volume":"22","author":"Beaupre","year":"2011","journal-title":"Osteoporosis Int"},{"issue":"5","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1210\/jc.2015-3467","article-title":"Preadmission bisphosphonate and mortality in critically ill patients","volume":"101","author":"Lee","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.2010.33.7485","article-title":"Use of bisphosphonates and reduced risk of colorectal cancer","volume":"29","author":"Rennert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar3224","article-title":"(Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis","volume":"13","author":"den Uyl","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis"},{"key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yjmcc.2016.08.017","article-title":"Vascular action of bisphosphonates: in vitro effect of alendronate on the regulation of cellular events involved in vessel pathogenesis","volume":"100","author":"Cutini","year":"2016","journal-title":"J Mol Cell Cardiol"},{"issue":"15","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00223-011-9549-2","article-title":"Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?","volume":"90","author":"Vestergaard","year":"2012","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/jbmr.3448","article-title":"Association of alendronate and risk of cardiovascular events in patients with hip fracture","volume":"33","author":"Sing","year":"2018","journal-title":"J Bone Mineral Res"},{"key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/clinem\/dgaa481","article-title":"Oral bisphosphonate use reduces cardiovascular events in a cohort of Danish patients referred for bone mineral density","volume":"105","author":"Rodr\u00edguez","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309390546000_","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122646","article-title":"Bisphosphonates and risk of cardiovascular events: a meta-analysis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"115296","DOI":"10.1016\/j.bone.2020.115296","article-title":"Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries","volume":"134","author":"Rubin","year":"2020","journal-title":"Bone"},{"issue":"5","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ije\/dym184","article-title":"Cohort profile: the 45 and up study","volume":"37","author":"Banks","year":"2008","journal-title":"Int J Epidemiol"},{"key":"2023041309390546000_","article-title":"Cohort profile update: the 45 and up study","author":"Bleicher","year":"2022","journal-title":"Int J Epidemiol"},{"issue":"5","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/jbmr.3374","article-title":"Comorbidities only account for a small proportion of excess mortality after fracture: A record linkage study of individual fracture types","volume":"33","author":"Chen","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2023041309390546000_","doi-asserted-by":"publisher","author":"Bliuc","DOI":"10.25833\/5j5v-dz82"},{"issue":"3","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/rtph.2002.1550","article-title":"Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study","volume":"35","author":"Steinbuch","year":"2002","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.4157","article-title":"Cardiovascular safety of denosumab across multiple indications: A systematic review and meta-analysis of randomized trials","volume":"36","author":"Seeto","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"115566","DOI":"10.1016\/j.bone.2020.115566","article-title":"Bisphosphonates and lifespan","volume":"141","author":"Center","year":"2020","journal-title":"Bone"},{"issue":"1","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mayocp.2013.08.021","article-title":"Myocardial infarction risk among patients with fractures receiving bisphosphonates","volume":"89","author":"Pittman","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2023041309390546000_","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2188\/jea.JE20150010","article-title":"Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death","volume":"26","author":"Mieno","year":"2016","journal-title":"J Epidemiol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac669\/47848845\/dgac669.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/5\/e110\/49873817\/dgac669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/5\/e110\/49873817\/dgac669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:15:54Z","timestamp":1701436554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/5\/e110\/6835060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,21]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac669","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,11,21]]}}}